Navigation Links
SuperGen Reports 2008 Second Quarter Financial Results
Date:8/4/2008

Quarterly Dacogen Royalty Revenue Increases 76% from Same Prior Year Period

DUBLIN, Calif., Aug. 4 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced financial results for the second quarter and six months ended June 30, 2008.

Total revenues for the 2008 second quarter were $8.1 million, compared with $4.6 million for the same prior year period. Total revenues for the 2008 second quarter and same prior year period consisted entirely of royalty revenue. Royalty revenue is earned pursuant to the license agreement entered into with MGI PHARMA (acquired by Eisai Co., Ltd. in January 2008) during 2004, which granted MGI PHARMA exclusive rights to the development, manufacture, commercialization and distribution of Dacogen(R) (decitabine) for Injection. The Company recognizes royalty revenue on a cash basis when it is received.

Excluding gain on sale of products, total costs and operating expenses for the 2008 second quarter were $11.0 million, compared with $19.6 million for the same prior year period. The primary reason for the decrease in total costs and operating expenses for the 2008 second quarter were lower acquired in-process research and development costs, a reduction in general corporate expenses and lower stock-based compensation expense offset in part by higher research and development costs related to increased product development activities including ongoing clinical operations and accrual of estimated severance costs in the amount of $322,000 related to the anticipated closure of our European operation later this year. Closure of the Europe
'/>"/>

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. SuperGen Reports 2008 First Quarter Financial Results
8. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. QMed, Inc. Reports July Medicare SNP Enrollments
11. Phlo Affiliate Reports Expanded Coverage to Oregon Border
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015 Kindred Biosciences, Inc. ... saving and improving the lives of pets, announced today that ... results on March 12, 2015 after the market close. The ... Time that day. Interested parties may access ... or (484) 756-4262 internationally, and using conference ID 98449349.  ...
(Date:3/3/2015)... 03, 2015 Cambridge Semantics, the leading ... technology, today announced that it has been named to ... in Knowledge Management.’ , To create the list ... analysts and system integrators who identify organizations dedicated to ... right information to the right people at the right ...
(Date:3/3/2015)... , Mar. 03, 2015 Research and ... the addition of Jain PharmaBiotech,s new report ... to their offering. , Gene ... vectors, nonviral vectors and cell therapy with genetically ... of drug delivery and various routes of administration ...
(Date:3/3/2015)... , March 3, 2015 DNA Diagnostics Center ... in the world, celebrates its 20 th anniversary ... , DDC is a consumer services company that focuses ... employs over 200 associates and generates a significant portion ... over 120 countries. Peter Vitulli ...
Breaking Biology Technology:Cambridge Semantics Named to KMWorld’s 2015 ‘100 Companies That Matter in Knowledge Management’ 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3DNA Diagnostics Center, One of The World's Largest DNA Testing Labs, Celebrates Their 20th Anniversary 2DNA Diagnostics Center, One of The World's Largest DNA Testing Labs, Celebrates Their 20th Anniversary 3
... Conn., Feb. 14 Biodel Inc. (Nasdaq:,BIOD) today reported ... The net loss for the quarter was $11.0 million ... pivotal Phase III clinical trials of,VIAject(TM) positions us to ... the FDA by the end of 2008," stated Dr. ...
... Product that Meets Regulatory &, Health Issues ... ORLANDO, Fla., Feb. 14 Valensa International ... the extraction of,Haematococcus pluvialis for the manufacture of ... of recently growing demand for a,high-quality astaxanthin in ...
... 2007 Launch; Positioned for Expanded Growth in ... U.S. and International Markets, Fourth Quarter and 2007 Financial Highlights:, ... compared to net product sales of $21.8 million in Q3 2007., ... a GAAP net loss of $20.1 million, or $0.55 per share, ...
Cached Biology Technology:Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 2Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 3Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 4Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 5Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 6Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 7Valensa Expands Astaxanthin Extraction Capacity 2Alexion Reports Fourth Quarter and Full Year 2007 Results 2Alexion Reports Fourth Quarter and Full Year 2007 Results 3Alexion Reports Fourth Quarter and Full Year 2007 Results 4Alexion Reports Fourth Quarter and Full Year 2007 Results 5Alexion Reports Fourth Quarter and Full Year 2007 Results 6Alexion Reports Fourth Quarter and Full Year 2007 Results 7Alexion Reports Fourth Quarter and Full Year 2007 Results 8Alexion Reports Fourth Quarter and Full Year 2007 Results 9Alexion Reports Fourth Quarter and Full Year 2007 Results 10Alexion Reports Fourth Quarter and Full Year 2007 Results 11Alexion Reports Fourth Quarter and Full Year 2007 Results 12Alexion Reports Fourth Quarter and Full Year 2007 Results 13
(Date:2/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT METHOD ... a new groundbreaking payment method. Payment accounts may be ... only be accessed if both the speech (the word ...
(Date:2/18/2015)... Feb. 18, 2015  Cepheid (NASDAQ: CPHD ) ... following conferences, and invited investors to participate via webcast. ... MA Tuesday, March 3, 2015 at 11.20 a.m. ... Orlando, FL Wednesday, March 4, 2015 at ... access the live webcasts for these events, please visit Cepheid,s ...
(Date:2/12/2015)... Feb. 12, 2015   MedNet Solutions , ... clinical study management systems, has recently bolstered its ... distinguishing iMedNet as the ... (CROs) and healthcare consultants.  Building on the Program,s ... referrals and numerous co-marketing opportunities), MedNet,s new and ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... threatened by exotic species of the moon jellyfish being ... Using genetic data and computer simulations of ocean currents ... South Wales and the University of California, Davis, have ... naturally, according to a report in today's Proceedings of ...
... has discovered how a gene that suppresses the development of ... way to treatments based on the function of the gene. ... Hormel Institute in Austin, Minn., have applied for a patent ... July 10 in the journal Nature Structural & Molecular Biology. ...
... suggested that ancient Neanderthals might have had an accelerated childhood ... based on a new assessment by researchers from Ohio State ... found that the rate of tooth growth present in the ... different populations of modern humans. , And since the ...
Cached Biology News:Ships bring alien jellyfish invaders to our shores 2Neanderthal teeth grew no faster than comparable modern humans' 2Neanderthal teeth grew no faster than comparable modern humans' 3
This kit is designed to select cells labeled with fluorescein isothiocyanate- (FITC-) conjugated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
... described by end-users to be "a delight ... of light microscopy and electronic imaging. With ... does not require much space and can ... environment. The DM-BA300 combines Motic's own revolutionary ...
lid holder -see Blotters (Semi-Dry) for more info...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human CD69 TAC is designed to deplete human CD69 from samples to isolate resting CD4+ or CD8+ T cells....
Biology Products: